Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer

ABSTRACT There is an unmet need to predict immune‐related adverse events (irAEs) in patients receiving immune checkpoint inhibitors. This study aimed to examine whether eosinophils can predict irAEs in metastatic urothelial carcinoma (mUC). In this multicenter cohort study, we retrospectively examin...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Kunihiro Odagiri, Yoshihiko Tasaki, Taku Naiki, Toshiharu Morikawa, Keitaro Iida, Yusuke Noda, Rika Banno, Teruki Isobe, Nobuhiko Shimizu, Maria Aoki, Yoshihisa Mimura, Yosuke Sugiyama, Takashi Nagai, Toshiki Etani, Shuzo Hamamoto, Ryosuke Ando, Noriyasu Kawai, Yoko Furukawa‐Hibi, Takahiro Yasui
Format:	Artigo
Język:	Inglês
Wydane:	Wiley 2026-07-01
Seria:	Cancer Medicine
Hasła przedmiotowe:	bladder cancer eosinophil immune‐related adverse event pembrolizumab urothelial carcinoma
Dostęp online:	https://doi.org/10.1002/cam4.72072
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!